ArticleTherapeutic advances in gastroenterology2011
Certolizumab pegol for the treatment of Crohn's disease.
Article in Therapeutic advances in gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01696942 (Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for Crohn's Disease at One Year Compared to Mesalamine), which is not on this map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for Crohn's Disease at One Year Compared to Mesalamine
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.World journal of gastroenterology · 2025Pooled it
- Certolizumab pegol for maintenance of medically induced remission in Crohn's disease.The Cochrane database of systematic reviews · 2022Pooled it
- Certolizumab pegol for induction of remission in Crohn's disease.The Cochrane database of systematic reviews · 2019Pooled it
- Biologic and targeted synthetic therapies in ankylosing spondylitis: a pharmacological review.Frontiers in pharmacology · 2026Review
- Impact of preoperative use of biologics on 30-day surgical morbidity and mortality in patients with Crohn's disease undergoing ileocolectomy: National Surgical Quality Improvement Program database analysis.Updates in surgery · 2025Article
- Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape.Small (Weinheim an der Bergstrasse, Germany) · 2025Review
- Certolizumab Pegol Treatment in Patients With Crohn's Disease: Final Safety Data From the SECURE Registry.Crohn's & colitis 360 · 2025Article
- Article
- Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems.Pharmaceutics · 2024Review
- Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.Clinical and experimental gastroenterology · 2024Review
- Effect of nanoparticle size on their distribution and retention in chronic inflammation sites.Discover nano · 2023Article
- Improvement of Work Productivity and Quality of Life with Anti-Tumor Necrosis Factor Treatment Used in Crohn's Disease in Routine Clinical Practice in Turkey.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Observational
- Development of Pharmaceutical Nanomedicines: From the Bench to the Market.Pharmaceutics · 2022Review
- Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy.World journal of stem cells · 2020Review
- Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.Clinical microbiology reviews · 2020Review
- Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products.Journal of clinical medicine · 2020Review
- Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia.Intestinal research · 2019Review
- Crohn's Disease: Potential Drugs for Modulation of Autophagy.Medicina (Kaunas, Lithuania) · 2019Review
- David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments.Antibodies (Basel, Switzerland) · 2019Review
- Effects of Anti-Cytokine Antibodies on Gut Barrier Function.Mediators of inflammation · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this article we provide a contemporary overview of available clinical data on certolizumab pegol, a pegylated anti-tumor necrosis factor (TNF) alpha agent that comprises a uniquely small protein, and its emerging role as a therapy for Crohn's disease (CD). The results from a comprehensive clinical trial program suggest that certolizumab pegol offers rapid and sustained remission of moderate to severe CD. Certolizumab pegol is an effective and well-tolerated therapy both in patients who have already received biologics and in patients who are anti-TNF naïve. Benefits of therapy include a stable dosing regimen, which allows for rapid induction of a clinical response followed by long-term maintenance of response and remission under one fixed dose. Treatment with certolizumab pegol has been shown to improve function and quality of life in patients with CD, and insights into the potential mechanisms by which certolizumab pegol effects a response in CD suggest that this agent may have the potential to slow or even modify disease progression. Early therapy is particularly effective and could help control CD progression and lessen the burden of disease on patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.